ROCKLAND, Mass.--(BUSINESS WIRE)--BioSphere Medical, Inc. (NASDAQ: BSMD) (“BioSphere”), a medical device company that has pioneered the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors, and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy, today reported that total revenue for the first quarter of 2008 increased 10% to $7.21 million from total revenue of $6.58 million for the first quarter of 2007. In the first quarter of 2008, revenue in the U.S. was $5.06 million, an increase of 10% compared to revenue of $4.60 million in the first quarter of 2007. Revenue in Europe, Mid-East and Africa (EMEA) rose 2% to $1.78 million for the first quarter of 2008 from $1.76 million for the same period in 2007. In markets outside of the United States and EMEA, revenue in Rest of World (ROW) markets increased 63% to $0.37 million for the first quarter of 2008 from $0.22 million for the same period in 2007.
